AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by AYTU BIOSCIENCE, INC. (also referred to as AYTU BIOPHARMA, INC.) on February 17, 2016, covering events occurring on February 10, 2016. The filing details the conversion of outstanding convertible notes into common stock and the issuance of related warrants.
Key Financial Metrics and Capital Structure
- Debt Conversion: An aggregate of $4,125,000 in principal and $142,810 in accrued interest on convertible notes was converted into equity.
- Shares Issued: The conversion resulted in the issuance of 7,879,096 shares of common stock.
- Warrants Issued: 267,073 warrants were issued to placement agents with an exercise price of $0.65 per share.
- Outstanding Debt: Following the conversion, $1,050,000 in principal amount of convertible notes remains outstanding.
- Share Count: Total common stock outstanding increased to 22,446,481 shares as of February 10, 2016.
- Revenue and Cash Flow: The filing text does not provide a clear value for revenue, profit, cash flow, or operating margins.
Material Changes Versus Prior Period
The primary material change is the significant reduction in debt and the corresponding increase in equity capitalization. The conversion was triggered by a prior event on January 20, 2016, where the CEO and COO purchased 307,692 shares at $0.65 per share, activating the conversion option for noteholders. The conversion price was set at 120% of the shares issuable based on the $0.65 price point.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the unregistered securities may not be offered or sold in the United States absent registration or an applicable exemption. The warrants issued have a cashless exercise feature and are exercisable for five years from the original note issuance dates in July and August 2015.
Key Facts for Investor Verification
- Verify the remaining $1,050,000 in outstanding convertible notes and their specific terms.
- Confirm the dilution impact of the 7,879,096 newly issued shares on existing shareholders.
- Review the terms of the 267,073 warrants issued to placement agents, specifically the cashless exercise provision.
- Check subsequent filings for the status of the remaining convertible notes and any further equity issuances.